Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Income from Continuing Operations (2016 - 2025)

Regenxbio (RGNX) has 12 years of Income from Continuing Operations data on record, last reported at 67167000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 31.01% year-over-year to 67167000.0; the TTM value through Dec 2025 reached 193961000.0, up 14.66%, while the annual FY2025 figure was 193961000.0, 242351.25% down from the prior year.
  • Income from Continuing Operations reached 67167000.0 in Q4 2025 per RGNX's latest filing, down from 61960000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 294079000.0 in Q4 2021 and bottomed at 76723000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 41858600.0, with a median of 61914000.0 recorded in 2023.
  • The widest YoY moves for Income from Continuing Operations: up 735.97% in 2021, down 764.37% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 294079000.0 in 2021, then tumbled by 120.36% to 59871000.0 in 2022, then dropped by 5.17% to 62969000.0 in 2023, then grew by 18.58% to 51269000.0 in 2024, then plummeted by 31.01% to 67167000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 67167000.0 in Q4 2025, 61960000.0 in Q3 2025, and 70892000.0 in Q2 2025.